# Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

> **NCT03752723** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** GX-I7
- **DRUG:** Pembrolizumab(KEYTRUDA®)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03752723
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-27
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03752723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03752723, "Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03752723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*